Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel
NASDAQ:NTRB

Nutriband Q1 2027 Earnings Results & Report

Nutriband logo
$6.65 +0.60 (+9.92%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$6.73 +0.08 (+1.14%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nutriband reported Q1 2027 earnings on June 11, 2026. The company reported EPS of -$0.10, while revenue was $0.43 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
After Market Closes

Nutriband EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Nutriband Revenue Results

Actual Revenue
$0.43 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Nutriband's next earnings date is estimated for Monday, December 7, 2026, based on past reporting schedules.

Conference Call Resources

Nutriband Q1 2027 Earnings FAQ

Nutriband (NASDAQ:NTRB) reported earnings of -$0.10 per share for Q1 2027. The report was announced on Thursday, June 11, 2026.

Nutriband reported revenue of $0.43 million for Q1 2027.

Nutriband's next earnings date is estimated for Monday, December 7, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nutriband on the company's earnings history page.

Nutriband Earnings Headlines

Nutriband Seeks New Patent Protection For AVERSA Transdermal Technology
October 8 at 7:58 PM  |  rttnews.comhttps://www.rttnews.com/3697543/nutriband-seeks-new-patent-protection-for-aversa-transdermal-technology.aspx
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
October 8 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377135/0/en/nutriband-files-new-patent-application-to-strengthen-intellectual-property-protection-of-its-transdermal-abuse-deterrent-technology.html
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
October 10 at 1:00 AM  |  Chaikin Analytics (Ad)
Nutriband Inc.: Nutriband Marks Five Years on Nasdaq - CEO Letter to Shareholders
October 2, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-10/69738932-nutriband-inc-nutriband-marks-five-years-on-nasdaq-ceo-letter-to-shareholders-399.htm
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373388/0/en/nutriband-marks-five-years-on-nasdaq-ceo-letter-to-shareholders.html
Financial Review: Evolus (NASDAQ:EOLS) vs. Nutriband (NASDAQ:NTRB)
September 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068051
See More Nutriband Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email.

About Nutriband

Nutriband (NASDAQ:NTRB) (NASDAQ:NTRB) develops and manufactures transdermal patches and other wearable drug-delivery products for pharmaceutical, over-the-counter, consumer, and wellness markets. The company’s capabilities include product development, formulation, manufacturing, packaging, and private-label services for customers seeking patch-based delivery systems.

Nutriband’s portfolio includes consumer and wellness patches, as well as prescription-focused transdermal technologies. Its AVERSA platform is designed to incorporate abuse-deterrent features into transdermal products, with the goal of helping reduce the risk of drug extraction, misuse, or abuse. The company has also pursued applications for controlled-substance delivery, including an abuse-deterrent fentanyl patch in development.

The company serves customers in pharmaceutical, healthcare, and consumer-product markets and operates from the United States. Nutriband became publicly traded on the Nasdaq under the symbol NTRB in 2022. Its business combines contract and private-label manufacturing with the development of proprietary transdermal technologies and branded patch products.

View Nutriband Profile
Earnings Tools